Skip to main content
Top
Published in: Archives of Gynecology and Obstetrics 4/2015

01-10-2015 | Gynecologic Oncology

Prognostic factors affecting cervical adenocarcinoma: 10 years experience in a single institution

Authors: J. Khalil, S. Bellefqih, M. Afif, H. Elkacemi, T. Kebdani, N. Benjaafar

Published in: Archives of Gynecology and Obstetrics | Issue 4/2015

Login to get access

Abstract

Objectives

We performed a population-based study to determine the significance of adenocarcinoma and to evaluate its behavior over the last 10 years among patients treated in the National cancer institute of Morocco.

Study design

This is a retrospective study that was conducted in the national cancer institute of Morocco. Over a period of 10 years, we retrieved 350 cases of cervical invasive adenocarcinoma. Survival was analyzed according to the Kaplan–Meier method. A univariate analysis of prognostic factors was performed using the test of log rank. Cox regression model was used for the multivariate analysis of prognostic factors.

Results

Mean age at presentation was 46 years. Sixty seven percent of the patients had locally advanced stage. Radiotherapy was prescribed in 73.3 % of the cases. The mean follow-up time for surviving patients was 51 months. The 5-year survival rates according to clinical stages were as follows, 76 and 62 % for stages I and II, respectively, 32 and 9 % for stages III and IV, respectively. Tumor stage, tumor grade, positive lymph nodes status, lymphovascular space involvement and patient’s age were significant prognostic factors in a univariate analysis. While only stage and lymph node involvement remained significant independent predictors for survival in the multivariate analysis.

Conclusion

Although in our country incidence of adenocarcinoma is lower than the ones reported in western countries, in general our results are consistent with those reported in the literature. Better outcomes are observed in both early stages and young patients. Also, we found that FIGO stage, grade and lymph node metastases to be significant prognostic factors for survival in cervical adenocarcinoma.
Literature
1.
go back to reference Bray F, Loos AH, McCarron P et al (2005) Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 14:677–686CrossRefPubMed Bray F, Loos AH, McCarron P et al (2005) Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 14:677–686CrossRefPubMed
2.
go back to reference Watson M, Saraiya M, Benard V et al (2008) Burden of cervical cancer in the United States, 1998–2003. Cancer 113:2855–2864CrossRefPubMed Watson M, Saraiya M, Benard V et al (2008) Burden of cervical cancer in the United States, 1998–2003. Cancer 113:2855–2864CrossRefPubMed
3.
go back to reference Bray F, Carstensen B, Moller H et al (2005) Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 14:2191–2199CrossRefPubMed Bray F, Carstensen B, Moller H et al (2005) Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 14:2191–2199CrossRefPubMed
4.
go back to reference Wang SS, Sherman ME, Hildesheim A et al (2004) Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000. Cancer 100:1035–1044CrossRefPubMed Wang SS, Sherman ME, Hildesheim A et al (2004) Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000. Cancer 100:1035–1044CrossRefPubMed
5.
go back to reference Galic V, Herzog TJ, Lewin SN, Neugut AI, Burke WM, Lu YS et al (2012) Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol 125:287–291CrossRefPubMed Galic V, Herzog TJ, Lewin SN, Neugut AI, Burke WM, Lu YS et al (2012) Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol 125:287–291CrossRefPubMed
6.
go back to reference Castellsague X, Diaz M, de Sanjose S et al (2006) Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98:303–315CrossRefPubMed Castellsague X, Diaz M, de Sanjose S et al (2006) Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98:303–315CrossRefPubMed
7.
go back to reference Mohanty G, Ghosh SN (2015) Risk factors for cancer of cervix, status of screening and methods for its detection. Arch Gynecol Obstet 291(2):247–249CrossRefPubMed Mohanty G, Ghosh SN (2015) Risk factors for cancer of cervix, status of screening and methods for its detection. Arch Gynecol Obstet 291(2):247–249CrossRefPubMed
8.
go back to reference Sasieni P, Castanon A, Cuzick J (2009) Screening and adenocarcinoma of the cervix. Int J Cancer 125:525–529CrossRefPubMed Sasieni P, Castanon A, Cuzick J (2009) Screening and adenocarcinoma of the cervix. Int J Cancer 125:525–529CrossRefPubMed
9.
go back to reference Lee YY, Choi CH, Kim TJ, Lee JW, Kim BG, Lee JH et al (2011) A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB–IIA. Gynecol Oncol 120:439–443CrossRefPubMed Lee YY, Choi CH, Kim TJ, Lee JW, Kim BG, Lee JH et al (2011) A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB–IIA. Gynecol Oncol 120:439–443CrossRefPubMed
10.
go back to reference Hopkins MP, Morley GW (1991) A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol 77:912–917PubMed Hopkins MP, Morley GW (1991) A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol 77:912–917PubMed
11.
go back to reference Baek M-H et al (2014) Comparison of adenocarcinoma and adenosquamous carcinoma in patients with early-stage cervical cancer after radical surgery. Gynecol Oncol 135(3):462–467CrossRefPubMed Baek M-H et al (2014) Comparison of adenocarcinoma and adenosquamous carcinoma in patients with early-stage cervical cancer after radical surgery. Gynecol Oncol 135(3):462–467CrossRefPubMed
12.
go back to reference Sivanesaratnam V (1998) Adjuvant chemotherapy in ‘‘high risk’’ patients after Wertheim hysterectomy: 10-year survivals. Ann Acad Med Singapore 27:622–626PubMed Sivanesaratnam V (1998) Adjuvant chemotherapy in ‘‘high risk’’ patients after Wertheim hysterectomy: 10-year survivals. Ann Acad Med Singapore 27:622–626PubMed
13.
go back to reference Chargui R, Damak T (2006) Prognostic factors and clinicopathologic characteristics of invasive adenocarcinoma of the uterine cervix. Am J Obstet Gynecol 194:43–48CrossRefPubMed Chargui R, Damak T (2006) Prognostic factors and clinicopathologic characteristics of invasive adenocarcinoma of the uterine cervix. Am J Obstet Gynecol 194:43–48CrossRefPubMed
14.
go back to reference Baalbergen A, Ewing-Graham PC, Hop WC, Struijk P, Helmerhost TJ (2004) Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol Oncol 92:262–267CrossRefPubMed Baalbergen A, Ewing-Graham PC, Hop WC, Struijk P, Helmerhost TJ (2004) Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol Oncol 92:262–267CrossRefPubMed
15.
go back to reference Chen RJ, Lin YH, Chen CA, Huang SC, Chow SN, Hsieh CY (1999) Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. Gynecol Oncol 73:184–190CrossRefPubMed Chen RJ, Lin YH, Chen CA, Huang SC, Chow SN, Hsieh CY (1999) Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. Gynecol Oncol 73:184–190CrossRefPubMed
16.
go back to reference Ishikawa H, Nakanishi T, Inoue T, Kuzuya K (1999) Prognostic factors of adenocarcinoma of the uterine cervix. Gynecol Oncol 73:42–46CrossRefPubMed Ishikawa H, Nakanishi T, Inoue T, Kuzuya K (1999) Prognostic factors of adenocarcinoma of the uterine cervix. Gynecol Oncol 73:42–46CrossRefPubMed
17.
go back to reference Kodama J, Seki N, Masahiro S et al (2010) Prognostic factors in stage IB–IIB cervical adenocarcinoma patients treated with radical hysterectomy and pelvic lymphadenectomy. J Surg Oncol 101:413–417PubMed Kodama J, Seki N, Masahiro S et al (2010) Prognostic factors in stage IB–IIB cervical adenocarcinoma patients treated with radical hysterectomy and pelvic lymphadenectomy. J Surg Oncol 101:413–417PubMed
18.
go back to reference Mabuchi S, Isohashi F, Yoshioka Y et al (2010) Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy. Int J Gynecol Cancer 20:834–840CrossRefPubMed Mabuchi S, Isohashi F, Yoshioka Y et al (2010) Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy. Int J Gynecol Cancer 20:834–840CrossRefPubMed
19.
go back to reference Nakanishi T, Ishikawa H, Suzuki Y, Inoue T, Nakamura S, Kuzuya K (2000) A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol Oncol 79:289–293CrossRefPubMed Nakanishi T, Ishikawa H, Suzuki Y, Inoue T, Nakamura S, Kuzuya K (2000) A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol Oncol 79:289–293CrossRefPubMed
20.
go back to reference Samlal RAK, van der Velden J, Ketting BW, Gonzalez Gonzalez D, ten Kate FJW, Hart AAM et al (1996) Disease-free interval and recurrence pattern after the Okabayashi variant of Wertheim’s radical hysterectomy for stage IB and IIA cervical carcinoma. Int J Gynecol Cancer 6:120–127CrossRef Samlal RAK, van der Velden J, Ketting BW, Gonzalez Gonzalez D, ten Kate FJW, Hart AAM et al (1996) Disease-free interval and recurrence pattern after the Okabayashi variant of Wertheim’s radical hysterectomy for stage IB and IIA cervical carcinoma. Int J Gynecol Cancer 6:120–127CrossRef
21.
go back to reference Chen RJ, Chang DY, Yen ML, Lee EF, Huang SC, Chow SN et al (1998) Prognostic factors of primary adenocarcinoma of the uterine cervix. Gynecol Oncol 69:157–164CrossRefPubMed Chen RJ, Chang DY, Yen ML, Lee EF, Huang SC, Chow SN et al (1998) Prognostic factors of primary adenocarcinoma of the uterine cervix. Gynecol Oncol 69:157–164CrossRefPubMed
22.
go back to reference Cuccia CA, Bloedorn FG, Onal M (1967) Treatment of primary adenocarcinoma of the cervix. Am J Roentgenol Radium Ther Nucl Med 99:371–375CrossRefPubMed Cuccia CA, Bloedorn FG, Onal M (1967) Treatment of primary adenocarcinoma of the cervix. Am J Roentgenol Radium Ther Nucl Med 99:371–375CrossRefPubMed
23.
go back to reference Hepler TK, Dockerty M, Randall LM (1952) Primary adenocarcinoma of the cervix. Am J Obstet Gynecol 63:800–808PubMed Hepler TK, Dockerty M, Randall LM (1952) Primary adenocarcinoma of the cervix. Am J Obstet Gynecol 63:800–808PubMed
24.
go back to reference Hurt WG, Silverberg SG, Frable WJ, Belgrad R, Crooks LD (1977) Adenocarcinoma of the cervix: histopathologic and clinical features. Am J Obstet Gynecol 129:304–315PubMed Hurt WG, Silverberg SG, Frable WJ, Belgrad R, Crooks LD (1977) Adenocarcinoma of the cervix: histopathologic and clinical features. Am J Obstet Gynecol 129:304–315PubMed
25.
go back to reference Kleine W, Rau K, Schwoeorer D, Pfleiderer A (1989) Prognosis of the adenocarcinoma of the cervix uteri: a comparative study. Gynecol Oncol 35:145–149CrossRefPubMed Kleine W, Rau K, Schwoeorer D, Pfleiderer A (1989) Prognosis of the adenocarcinoma of the cervix uteri: a comparative study. Gynecol Oncol 35:145–149CrossRefPubMed
26.
go back to reference Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH (2010) Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix. Br J Cancer 102:1692–1698PubMedCentralCrossRefPubMed Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH (2010) Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix. Br J Cancer 102:1692–1698PubMedCentralCrossRefPubMed
27.
go back to reference Eifel PJ, Morris M, Oswald MJ, Wharton JT, Delclos L (1990) Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases. Cancer 65:2507–2514CrossRefPubMed Eifel PJ, Morris M, Oswald MJ, Wharton JT, Delclos L (1990) Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases. Cancer 65:2507–2514CrossRefPubMed
28.
go back to reference Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P et al (1997) Randomized study of radical surgery versus radiotherapy for stage Ib–IIa cervical cancer. Lancet 350:535–540CrossRefPubMed Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P et al (1997) Randomized study of radical surgery versus radiotherapy for stage Ib–IIa cervical cancer. Lancet 350:535–540CrossRefPubMed
29.
go back to reference Baalbergen A, Veenstra Y, Stalpers L (2013) Primary surgery versus primary radiotherapy with or without chemotherapy for early adenocarcinoma of the uterine cervix. Cochrane Database Syst Rev 1:CD006248PubMed Baalbergen A, Veenstra Y, Stalpers L (2013) Primary surgery versus primary radiotherapy with or without chemotherapy for early adenocarcinoma of the uterine cervix. Cochrane Database Syst Rev 1:CD006248PubMed
30.
go back to reference Monk BJ, Wang J, Im S, Stock RJ, Peters WA, Liu PY et al (2005) Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical–pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol 96:721–728CrossRefPubMed Monk BJ, Wang J, Im S, Stock RJ, Peters WA, Liu PY et al (2005) Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical–pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol 96:721–728CrossRefPubMed
31.
go back to reference Nagao S, Fujiwara K, Oda T, Ishikawa H, Koike H, Tanaka H et al (2005) Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer: a pilot study. Gynecol Oncol 96:805–809CrossRefPubMed Nagao S, Fujiwara K, Oda T, Ishikawa H, Koike H, Tanaka H et al (2005) Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer: a pilot study. Gynecol Oncol 96:805–809CrossRefPubMed
32.
go back to reference Kastratis E, Bamias A, Efstathiou E, Gika D, Bozas G, Zorzou P et al (2005) The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. Gynecol Oncol 99:376–382CrossRef Kastratis E, Bamias A, Efstathiou E, Gika D, Bozas G, Zorzou P et al (2005) The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. Gynecol Oncol 99:376–382CrossRef
33.
go back to reference Tang J, Tang Y, Yang J, Huang S (2012) Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma. Gynecol Oncol 125:297–302CrossRefPubMed Tang J, Tang Y, Yang J, Huang S (2012) Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma. Gynecol Oncol 125:297–302CrossRefPubMed
34.
go back to reference Kitchener HC, Hoskins W, Small W Jr, Thomas GM, Trimble EL (2010) The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report. Int J Gynecol Cancer 20:1092–1100CrossRefPubMed Kitchener HC, Hoskins W, Small W Jr, Thomas GM, Trimble EL (2010) The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report. Int J Gynecol Cancer 20:1092–1100CrossRefPubMed
35.
go back to reference Kurtz JE, Hardy-Bessard AC, Deslandres M, Lavau-Denis S, Largillier R, Roemer-Becuwe C et al (2009) Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial. Gynecol Oncol 113:16–20CrossRefPubMed Kurtz JE, Hardy-Bessard AC, Deslandres M, Lavau-Denis S, Largillier R, Roemer-Becuwe C et al (2009) Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial. Gynecol Oncol 113:16–20CrossRefPubMed
36.
go back to reference Del Campo JM, Prat A, Gil-Moreno A, Perez J, Parera M (2008) Update on novel therapeutic agents for cervical cancer. Gynecol Oncol 110:S72–S76CrossRefPubMed Del Campo JM, Prat A, Gil-Moreno A, Perez J, Parera M (2008) Update on novel therapeutic agents for cervical cancer. Gynecol Oncol 110:S72–S76CrossRefPubMed
Metadata
Title
Prognostic factors affecting cervical adenocarcinoma: 10 years experience in a single institution
Authors
J. Khalil
S. Bellefqih
M. Afif
H. Elkacemi
T. Kebdani
N. Benjaafar
Publication date
01-10-2015
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 4/2015
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-015-3701-6

Other articles of this Issue 4/2015

Archives of Gynecology and Obstetrics 4/2015 Go to the issue